AU2026201484A1 — Solid state forms
Assigned to Amgen Inc · Expires 2026-03-19 · 0y expired
What this patent protects
SOLID STATE FORMS The present disclosure provides crystalline and amorphous forms of 6-fluoro- 7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2- methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydra…
USPTO Abstract
SOLID STATE FORMS The present disclosure provides crystalline and amorphous forms of 6-fluoro- 7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2- methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition. FIG. 1 3600 Intensity (counts) 1600 400 0 5 10 15 20 25 30 35 2Theta (9) G12C inhibition. 20 26 20 14 84 26 F eb 2 02 6 2 6 F e b 2 0 2 6 A b s t r a c t 2 0 2 6 2 0 1 4 8 4 3 6 0 0 Intensity (counts) 1 6 0 0 0 5 2 0 2 5 3 0 3 5
Drugs covered by this patent
- Lumakras (SOTORASIB) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.